Incidence and mortality due to thromboembolic events during the COVID-19 pandemic: Multi-sourced population-based health records cohort study
Evidence supports an excess of deaths during the COVID-19 pandemic. We report the incidence and mortality of thrombo-embolic events (TE) during the COVID-19 pandemic. Multi-sourced nationwide cohort study of adults (age ≥18 years) admitted to hospital with TE and deaths from TE in England (hospital...
Uloženo v:
| Vydáno v: | Thrombosis research Ročník 202; s. 17 - 23 |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
Elsevier Ltd
01.06.2021
|
| Témata: | |
| ISSN: | 0049-3848, 1879-2472, 1879-2472 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Evidence supports an excess of deaths during the COVID-19 pandemic. We report the incidence and mortality of thrombo-embolic events (TE) during the COVID-19 pandemic.
Multi-sourced nationwide cohort study of adults (age ≥18 years) admitted to hospital with TE and deaths from TE in England (hospital and community) between 1st February 2018 and 31st July 2020. Relative risks, adjusted for age, sex, atrial fibrillation, co-morbidities and time trend comparing before and during the COVID-19 pandemic were estimated using Poisson regression.
Of 272,423 patients admitted with TE to 195 hospitals, 86,577 (31.8%) were admitted after 2nd March 2020 (first COVID-19 death in the UK). The incidence of TE hospitalised increased during the COVID-19 pandemic from 1090 to 1590 per 100,000 (absolute risk change 45.9% [95% CI 45.1–46.6%], adjusted relative risk [ARR] 1.43 [95% CI 1.41–1.44]) driven particularly by pulmonary embolism; 1.49, 95% CI 1.46–1.52. TE were more frequent among those with COVID-19; 1.9% vs. 1.6%, absolute risk change 21.7%, 95% CI 21.0–22.4%, ARR 1.20, 95% CI 1.18–1.22. There was an increase in the overall mortality from TE during the pandemic (617, 6.7% proportional increase compared with the historical baseline), with more TE deaths occurring in the community compared with the historical rate (44% vs. 33%).
The COVID-19 pandemic has resulted in an increase in the incidence of hospitalised TE. There were more deaths from TE in the community highlighting a number of mechanisms including the hypercoagulable state associated with COVID-19 infection and potential impact of delays in seeking help.
Evidence before this study
We searched PubMed on 16 November 2020 for articles that documented the incidence and mortality of thrombo-embolic events (TE) during the COVID-19 pandemic using the search terms “COVID-19” OR “Coronavirus*” OR “2019-nCOV” OR “SARS-CoV” AND (“Thromboembolism” OR “Venous Thromboembolism” OR “thromboembol*”) with no language or time restrictions. The majority of data on TE in COVID-19 pertains to hospitalised patients from retrospective cohort studies. One study found that TE in hospitalised patients was associated with an increased mortality rate (adjusted hazard ratio 1.82; 95% CI 1.54–2.15). A systematic review and meta-analysis of 35 studies in 9249 hospitalised patients calculated an overall pooled incidence of TE of 17.8% (95% CI: 9.9–27.4%), rising to 22.9% (95% CI: 14.5–32.4%) in patients admitted to intensive care (ICU). The most contemporary data are from a cohort of 1114 patients (715 outpatient, 399 hospitalised, 170 admitted to ICU). With robust COVID-19-specific therapies and widespread thromboprophylaxis the prevalence of venous TE in ICU patients was reported as 7% (n = 12) when catheter-/device-related events were excluded, and among the outpatients there was no TE reported. No published studies have used nationwide data to investigate TE during the pandemic or the effect of the pandemic on outcomes of patients with TE but without Covid-19.
Added value of this study
This retrospective multi-sourced nationwide unlinked cohort study compares the overall incidence and mortality of TE prior to and during the COVID-19 pandemic. We found an increased incidence of TE despite only a small proportion having a diagnosis of COVID-19. This may highlight the lack of testing, particularly in the community during the initial phase of the pandemic, and the possibility of other factors contributing to TE risk, such as decreased daily activity mandated by home quarantine and alterations in medication concordance. Mortality from TE was higher in the community during the pandemic and this highlights that adverse societal effects of the pandemic, such as aversion to seeking medical assessment, may precipitate worse outcomes related to TE.
Implications of all the available evidence
Evidence suggests that COVID-19 produces a hypercoagulable state and thromboprophylaxis is recommended in hospitalised patients to prevent excess mortality from TE. Whether to anticoagulate non-hospitalised ambulatory patients with COVID-19 will be answered by ongoing trials. Clinicians should consider the risks posed by decreased daily activity and fear of medical contact, and provide appropriate advice to patients.
[Display omitted]
•Thrombo-embolic event (TE) have been described as one of the major cardiovascular complications of COVID-19.•The incidence of TE hospitalised increased during the COVID-19 pandemic.•The increase was driven particularly by pulmonary embolism.•TE were more frequent among those with COVID-19.•More TE deaths occurred in the community during the COVID-19 pandemic compared with the previous years. |
|---|---|
| AbstractList | Evidence supports an excess of deaths during the COVID-19 pandemic. We report the incidence and mortality of thrombo-embolic events (TE) during the COVID-19 pandemic.
Multi-sourced nationwide cohort study of adults (age ≥18 years) admitted to hospital with TE and deaths from TE in England (hospital and community) between 1st February 2018 and 31st July 2020. Relative risks, adjusted for age, sex, atrial fibrillation, co-morbidities and time trend comparing before and during the COVID-19 pandemic were estimated using Poisson regression.
Of 272,423 patients admitted with TE to 195 hospitals, 86,577 (31.8%) were admitted after 2nd March 2020 (first COVID-19 death in the UK). The incidence of TE hospitalised increased during the COVID-19 pandemic from 1090 to 1590 per 100,000 (absolute risk change 45.9% [95% CI 45.1-46.6%], adjusted relative risk [ARR] 1.43 [95% CI 1.41-1.44]) driven particularly by pulmonary embolism; 1.49, 95% CI 1.46-1.52. TE were more frequent among those with COVID-19; 1.9% vs. 1.6%, absolute risk change 21.7%, 95% CI 21.0-22.4%, ARR 1.20, 95% CI 1.18-1.22. There was an increase in the overall mortality from TE during the pandemic (617, 6.7% proportional increase compared with the historical baseline), with more TE deaths occurring in the community compared with the historical rate (44% vs. 33%).
The COVID-19 pandemic has resulted in an increase in the incidence of hospitalised TE. There were more deaths from TE in the community highlighting a number of mechanisms including the hypercoagulable state associated with COVID-19 infection and potential impact of delays in seeking help.
Evidence before this study We searched PubMed on 16 November 2020 for articles that documented the incidence and mortality of thrombo-embolic events (TE) during the COVID-19 pandemic using the search terms "COVID-19" OR "Coronavirus*" OR "2019-nCOV" OR "SARS-CoV" AND ("Thromboembolism" OR "Venous Thromboembolism" OR "thromboembol*") with no language or time restrictions. The majority of data on TE in COVID-19 pertains to hospitalised patients from retrospective cohort studies. One study found that TE in hospitalised patients was associated with an increased mortality rate (adjusted hazard ratio 1.82; 95% CI 1.54-2.15). A systematic review and meta-analysis of 35 studies in 9249 hospitalised patients calculated an overall pooled incidence of TE of 17.8% (95% CI: 9.9-27.4%), rising to 22.9% (95% CI: 14.5-32.4%) in patients admitted to intensive care (ICU). The most contemporary data are from a cohort of 1114 patients (715 outpatient, 399 hospitalised, 170 admitted to ICU). With robust COVID-19-specific therapies and widespread thromboprophylaxis the prevalence of venous TE in ICU patients was reported as 7% (n = 12) when catheter-/device-related events were excluded, and among the outpatients there was no TE reported. No published studies have used nationwide data to investigate TE during the pandemic or the effect of the pandemic on outcomes of patients with TE but without Covid-19. Added value of this study This retrospective multi-sourced nationwide unlinked cohort study compares the overall incidence and mortality of TE prior to and during the COVID-19 pandemic. We found an increased incidence of TE despite only a small proportion having a diagnosis of COVID-19. This may highlight the lack of testing, particularly in the community during the initial phase of the pandemic, and the possibility of other factors contributing to TE risk, such as decreased daily activity mandated by home quarantine and alterations in medication concordance. Mortality from TE was higher in the community during the pandemic and this highlights that adverse societal effects of the pandemic, such as aversion to seeking medical assessment, may precipitate worse outcomes related to TE. Implications of all the available evidence Evidence suggests that COVID-19 produces a hypercoagulable state and thromboprophylaxis is recommended in hospitalised patients to prevent excess mortality from TE. Whether to anticoagulate non-hospitalised ambulatory patients with COVID-19 will be answered by ongoing trials. Clinicians should consider the risks posed by decreased daily activity and fear of medical contact, and provide appropriate advice to patients. Unlabelled Image Evidence supports an excess of deaths during the COVID-19 pandemic. We report the incidence and mortality of thrombo-embolic events (TE) during the COVID-19 pandemic. Multi-sourced nationwide cohort study of adults (age ≥18 years) admitted to hospital with TE and deaths from TE in England (hospital and community) between 1st February 2018 and 31st July 2020. Relative risks, adjusted for age, sex, atrial fibrillation, co-morbidities and time trend comparing before and during the COVID-19 pandemic were estimated using Poisson regression. Of 272,423 patients admitted with TE to 195 hospitals, 86,577 (31.8%) were admitted after 2nd March 2020 (first COVID-19 death in the UK). The incidence of TE hospitalised increased during the COVID-19 pandemic from 1090 to 1590 per 100,000 (absolute risk change 45.9% [95% CI 45.1–46.6%], adjusted relative risk [ARR] 1.43 [95% CI 1.41–1.44]) driven particularly by pulmonary embolism; 1.49, 95% CI 1.46–1.52. TE were more frequent among those with COVID-19; 1.9% vs. 1.6%, absolute risk change 21.7%, 95% CI 21.0–22.4%, ARR 1.20, 95% CI 1.18–1.22. There was an increase in the overall mortality from TE during the pandemic (617, 6.7% proportional increase compared with the historical baseline), with more TE deaths occurring in the community compared with the historical rate (44% vs. 33%). The COVID-19 pandemic has resulted in an increase in the incidence of hospitalised TE. There were more deaths from TE in the community highlighting a number of mechanisms including the hypercoagulable state associated with COVID-19 infection and potential impact of delays in seeking help. Evidence before this study We searched PubMed on 16 November 2020 for articles that documented the incidence and mortality of thrombo-embolic events (TE) during the COVID-19 pandemic using the search terms “COVID-19” OR “Coronavirus*” OR “2019-nCOV” OR “SARS-CoV” AND (“Thromboembolism” OR “Venous Thromboembolism” OR “thromboembol*”) with no language or time restrictions. The majority of data on TE in COVID-19 pertains to hospitalised patients from retrospective cohort studies. One study found that TE in hospitalised patients was associated with an increased mortality rate (adjusted hazard ratio 1.82; 95% CI 1.54–2.15). A systematic review and meta-analysis of 35 studies in 9249 hospitalised patients calculated an overall pooled incidence of TE of 17.8% (95% CI: 9.9–27.4%), rising to 22.9% (95% CI: 14.5–32.4%) in patients admitted to intensive care (ICU). The most contemporary data are from a cohort of 1114 patients (715 outpatient, 399 hospitalised, 170 admitted to ICU). With robust COVID-19-specific therapies and widespread thromboprophylaxis the prevalence of venous TE in ICU patients was reported as 7% (n = 12) when catheter-/device-related events were excluded, and among the outpatients there was no TE reported. No published studies have used nationwide data to investigate TE during the pandemic or the effect of the pandemic on outcomes of patients with TE but without Covid-19. Added value of this study This retrospective multi-sourced nationwide unlinked cohort study compares the overall incidence and mortality of TE prior to and during the COVID-19 pandemic. We found an increased incidence of TE despite only a small proportion having a diagnosis of COVID-19. This may highlight the lack of testing, particularly in the community during the initial phase of the pandemic, and the possibility of other factors contributing to TE risk, such as decreased daily activity mandated by home quarantine and alterations in medication concordance. Mortality from TE was higher in the community during the pandemic and this highlights that adverse societal effects of the pandemic, such as aversion to seeking medical assessment, may precipitate worse outcomes related to TE. Implications of all the available evidence Evidence suggests that COVID-19 produces a hypercoagulable state and thromboprophylaxis is recommended in hospitalised patients to prevent excess mortality from TE. Whether to anticoagulate non-hospitalised ambulatory patients with COVID-19 will be answered by ongoing trials. Clinicians should consider the risks posed by decreased daily activity and fear of medical contact, and provide appropriate advice to patients. [Display omitted] •Thrombo-embolic event (TE) have been described as one of the major cardiovascular complications of COVID-19.•The incidence of TE hospitalised increased during the COVID-19 pandemic.•The increase was driven particularly by pulmonary embolism.•TE were more frequent among those with COVID-19.•More TE deaths occurred in the community during the COVID-19 pandemic compared with the previous years. Evidence supports an excess of deaths during the COVID-19 pandemic. We report the incidence and mortality of thrombo-embolic events (TE) during the COVID-19 pandemic.BACKGROUNDEvidence supports an excess of deaths during the COVID-19 pandemic. We report the incidence and mortality of thrombo-embolic events (TE) during the COVID-19 pandemic.Multi-sourced nationwide cohort study of adults (age ≥18 years) admitted to hospital with TE and deaths from TE in England (hospital and community) between 1st February 2018 and 31st July 2020. Relative risks, adjusted for age, sex, atrial fibrillation, co-morbidities and time trend comparing before and during the COVID-19 pandemic were estimated using Poisson regression.METHODSMulti-sourced nationwide cohort study of adults (age ≥18 years) admitted to hospital with TE and deaths from TE in England (hospital and community) between 1st February 2018 and 31st July 2020. Relative risks, adjusted for age, sex, atrial fibrillation, co-morbidities and time trend comparing before and during the COVID-19 pandemic were estimated using Poisson regression.Of 272,423 patients admitted with TE to 195 hospitals, 86,577 (31.8%) were admitted after 2nd March 2020 (first COVID-19 death in the UK). The incidence of TE hospitalised increased during the COVID-19 pandemic from 1090 to 1590 per 100,000 (absolute risk change 45.9% [95% CI 45.1-46.6%], adjusted relative risk [ARR] 1.43 [95% CI 1.41-1.44]) driven particularly by pulmonary embolism; 1.49, 95% CI 1.46-1.52. TE were more frequent among those with COVID-19; 1.9% vs. 1.6%, absolute risk change 21.7%, 95% CI 21.0-22.4%, ARR 1.20, 95% CI 1.18-1.22. There was an increase in the overall mortality from TE during the pandemic (617, 6.7% proportional increase compared with the historical baseline), with more TE deaths occurring in the community compared with the historical rate (44% vs. 33%).FINDINGSOf 272,423 patients admitted with TE to 195 hospitals, 86,577 (31.8%) were admitted after 2nd March 2020 (first COVID-19 death in the UK). The incidence of TE hospitalised increased during the COVID-19 pandemic from 1090 to 1590 per 100,000 (absolute risk change 45.9% [95% CI 45.1-46.6%], adjusted relative risk [ARR] 1.43 [95% CI 1.41-1.44]) driven particularly by pulmonary embolism; 1.49, 95% CI 1.46-1.52. TE were more frequent among those with COVID-19; 1.9% vs. 1.6%, absolute risk change 21.7%, 95% CI 21.0-22.4%, ARR 1.20, 95% CI 1.18-1.22. There was an increase in the overall mortality from TE during the pandemic (617, 6.7% proportional increase compared with the historical baseline), with more TE deaths occurring in the community compared with the historical rate (44% vs. 33%).The COVID-19 pandemic has resulted in an increase in the incidence of hospitalised TE. There were more deaths from TE in the community highlighting a number of mechanisms including the hypercoagulable state associated with COVID-19 infection and potential impact of delays in seeking help.INTERPRETATIONThe COVID-19 pandemic has resulted in an increase in the incidence of hospitalised TE. There were more deaths from TE in the community highlighting a number of mechanisms including the hypercoagulable state associated with COVID-19 infection and potential impact of delays in seeking help.Evidence before this study We searched PubMed on 16 November 2020 for articles that documented the incidence and mortality of thrombo-embolic events (TE) during the COVID-19 pandemic using the search terms "COVID-19" OR "Coronavirus*" OR "2019-nCOV" OR "SARS-CoV" AND ("Thromboembolism" OR "Venous Thromboembolism" OR "thromboembol*") with no language or time restrictions. The majority of data on TE in COVID-19 pertains to hospitalised patients from retrospective cohort studies. One study found that TE in hospitalised patients was associated with an increased mortality rate (adjusted hazard ratio 1.82; 95% CI 1.54-2.15). A systematic review and meta-analysis of 35 studies in 9249 hospitalised patients calculated an overall pooled incidence of TE of 17.8% (95% CI: 9.9-27.4%), rising to 22.9% (95% CI: 14.5-32.4%) in patients admitted to intensive care (ICU). The most contemporary data are from a cohort of 1114 patients (715 outpatient, 399 hospitalised, 170 admitted to ICU). With robust COVID-19-specific therapies and widespread thromboprophylaxis the prevalence of venous TE in ICU patients was reported as 7% (n = 12) when catheter-/device-related events were excluded, and among the outpatients there was no TE reported. No published studies have used nationwide data to investigate TE during the pandemic or the effect of the pandemic on outcomes of patients with TE but without Covid-19. Added value of this study This retrospective multi-sourced nationwide unlinked cohort study compares the overall incidence and mortality of TE prior to and during the COVID-19 pandemic. We found an increased incidence of TE despite only a small proportion having a diagnosis of COVID-19. This may highlight the lack of testing, particularly in the community during the initial phase of the pandemic, and the possibility of other factors contributing to TE risk, such as decreased daily activity mandated by home quarantine and alterations in medication concordance. Mortality from TE was higher in the community during the pandemic and this highlights that adverse societal effects of the pandemic, such as aversion to seeking medical assessment, may precipitate worse outcomes related to TE. Implications of all the available evidence Evidence suggests that COVID-19 produces a hypercoagulable state and thromboprophylaxis is recommended in hospitalised patients to prevent excess mortality from TE. Whether to anticoagulate non-hospitalised ambulatory patients with COVID-19 will be answered by ongoing trials. Clinicians should consider the risks posed by decreased daily activity and fear of medical contact, and provide appropriate advice to patients.RESEARCH IN CONTEXTEvidence before this study We searched PubMed on 16 November 2020 for articles that documented the incidence and mortality of thrombo-embolic events (TE) during the COVID-19 pandemic using the search terms "COVID-19" OR "Coronavirus*" OR "2019-nCOV" OR "SARS-CoV" AND ("Thromboembolism" OR "Venous Thromboembolism" OR "thromboembol*") with no language or time restrictions. The majority of data on TE in COVID-19 pertains to hospitalised patients from retrospective cohort studies. One study found that TE in hospitalised patients was associated with an increased mortality rate (adjusted hazard ratio 1.82; 95% CI 1.54-2.15). A systematic review and meta-analysis of 35 studies in 9249 hospitalised patients calculated an overall pooled incidence of TE of 17.8% (95% CI: 9.9-27.4%), rising to 22.9% (95% CI: 14.5-32.4%) in patients admitted to intensive care (ICU). The most contemporary data are from a cohort of 1114 patients (715 outpatient, 399 hospitalised, 170 admitted to ICU). With robust COVID-19-specific therapies and widespread thromboprophylaxis the prevalence of venous TE in ICU patients was reported as 7% (n = 12) when catheter-/device-related events were excluded, and among the outpatients there was no TE reported. No published studies have used nationwide data to investigate TE during the pandemic or the effect of the pandemic on outcomes of patients with TE but without Covid-19. Added value of this study This retrospective multi-sourced nationwide unlinked cohort study compares the overall incidence and mortality of TE prior to and during the COVID-19 pandemic. We found an increased incidence of TE despite only a small proportion having a diagnosis of COVID-19. This may highlight the lack of testing, particularly in the community during the initial phase of the pandemic, and the possibility of other factors contributing to TE risk, such as decreased daily activity mandated by home quarantine and alterations in medication concordance. Mortality from TE was higher in the community during the pandemic and this highlights that adverse societal effects of the pandemic, such as aversion to seeking medical assessment, may precipitate worse outcomes related to TE. Implications of all the available evidence Evidence suggests that COVID-19 produces a hypercoagulable state and thromboprophylaxis is recommended in hospitalised patients to prevent excess mortality from TE. Whether to anticoagulate non-hospitalised ambulatory patients with COVID-19 will be answered by ongoing trials. Clinicians should consider the risks posed by decreased daily activity and fear of medical contact, and provide appropriate advice to patients. AbstractBackgroundEvidence supports an excess of deaths during the COVID-19 pandemic. We report the incidence and mortality of thrombo-embolic events (TE) during the COVID-19 pandemic. MethodsMulti-sourced nationwide cohort study of adults (age ≥18 years) admitted to hospital with TE and deaths from TE in England (hospital and community) between 1st February 2018 and 31st July 2020. Relative risks, adjusted for age, sex, atrial fibrillation, co-morbidities and time trend comparing before and during the COVID-19 pandemic were estimated using Poisson regression. FindingsOf 268,054 patients admitted with TE to 195 hospitals, 82,208 (30.6%) were admitted after 2nd March 2020 (first COVID-19 death in the UK). The incidence of TE hospitalised increased during the COVID-19 pandemic from 1090 to 1517 per 100,000 (absolute risk change 45.9% [95% CI 45.1–46.6%], adjusted relative risk [ARR] 1.43 [95% CI 1.41–1.44]) driven particularly by pulmonary embolism; 1.49, 95% CI 1.46–1.52. TE were more frequent among those with COVID-19; 1.9% vs. 1.6%, absolute risk change 21.7%, 95% CI 21.0–22.4%, ARR 1.20, 95% CI 1.18–1.22. There was an increase in the overall mortality from TE during the pandemic (617, 6.7% proportional increase compared with the historical baseline), with more TE deaths occurring in the community compared with the historical rate (44% vs. 33%). InterpretationThe COVID-19 pandemic has resulted in an increase in the incidence of hospitalised TE. There were more deaths from TE in the community highlighting a number of mechanisms including the hypercoagulable state associated with COVID-19 infection and potential impact of delays in seeking help. Research in contextEvidence before this study We searched PubMed on 16 November 2020 for articles that documented the incidence and mortality of thrombo-embolic events (TE) during the COVID-19 pandemic using the search terms “COVID-19” OR “Coronavirus*” OR “2019-nCOV” OR “SARS-CoV” AND (“Thromboembolism” OR “Venous Thromboembolism” OR “thromboembol*”) with no language or time restrictions. The majority of data on TE in COVID-19 pertains to hospitalised patients from retrospective cohort studies. One study found that TE in hospitalised patients was associated with an increased mortality rate (adjusted hazard ratio 1.82; 95% CI 1.54–2.15). A systematic review and meta-analysis of 35 studies in 9249 hospitalised patients calculated an overall pooled incidence of TE of 17.8% (95% CI: 9.9–27.4%), rising to 22.9% (95% CI: 14.5–32.4%) in patients admitted to intensive care (ICU). The most contemporary data are from a cohort of 1114 patients (715 outpatient, 399 hospitalised, 170 admitted to ICU). With robust COVID-19-specific therapies and widespread thromboprophylaxis the prevalence of venous TE in ICU patients was reported as 7% ( n = 12) when catheter-/device-related events were excluded, and among the outpatients there was no TE reported. No published studies have used nationwide data to investigate TE during the pandemic or the effect of the pandemic on outcomes of patients with TE but without Covid-19. Added value of this study This retrospective multi-sourced nationwide unlinked cohort study compares the overall incidence and mortality of TE prior to and during the COVID-19 pandemic. We found an increased incidence of TE despite only a small proportion having a diagnosis of COVID-19. This may highlight the lack of testing, particularly in the community during the initial phase of the pandemic, and the possibility of other factors contributing to TE risk, such as decreased daily activity mandated by home quarantine and alterations in medication concordance. Mortality from TE was higher in the community during the pandemic and this highlights that adverse societal effects of the pandemic, such as aversion to seeking medical assessment, may precipitate worse outcomes related to TE. Implications of all the available evidence Evidence suggests that COVID-19 produces a hypercoagulable state and thromboprophylaxis is recommended in hospitalised patients to prevent excess mortality from TE. Whether to anticoagulate non-hospitalised ambulatory patients with COVID-19 will be answered by ongoing trials. Clinicians should consider the risks posed by decreased daily activity and fear of medical contact, and provide appropriate advice to patients. |
| Author | Wu, Jianhua Deanfield, John Nadarajah, Ramesh Gale, Chris P. Aktaa, Suleman de Belder, Mark Rashid, Muhammad Mamas, Mamas A. |
| Author_xml | – sequence: 1 givenname: Suleman surname: Aktaa fullname: Aktaa, Suleman email: s.aktaa@leeds.ac.uk organization: Leeds Institute for Data Analytics, University of Leeds, UK – sequence: 2 givenname: Jianhua surname: Wu fullname: Wu, Jianhua organization: Leeds Institute for Data Analytics, University of Leeds, UK – sequence: 3 givenname: Ramesh surname: Nadarajah fullname: Nadarajah, Ramesh organization: Leeds Institute for Data Analytics, University of Leeds, UK – sequence: 4 givenname: Muhammad surname: Rashid fullname: Rashid, Muhammad organization: Keele Cardiovascular Research Group, Centre for Prognosis Research, Institutes of Applied Clinical Science and Primary Care and Health Sciences, Keele University, UK – sequence: 5 givenname: Mark surname: de Belder fullname: de Belder, Mark organization: National Institute of Cardiovascular Outcomes Research (NICOR), Barts Health NHS Trust, UK – sequence: 6 givenname: John surname: Deanfield fullname: Deanfield, John organization: National Institute of Cardiovascular Outcomes Research (NICOR), Barts Health NHS Trust, UK – sequence: 7 givenname: Mamas A. surname: Mamas fullname: Mamas, Mamas A. organization: Keele Cardiovascular Research Group, Centre for Prognosis Research, Institutes of Applied Clinical Science and Primary Care and Health Sciences, Keele University, UK – sequence: 8 givenname: Chris P. surname: Gale fullname: Gale, Chris P. organization: Leeds Institute for Data Analytics, University of Leeds, UK |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33711754$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNUstu1DAUjVARnRZ-ofKSTYIfSZwgVIGG10hFXfDYWo59p-PBsae2M9J8BP-Mp9NW0AVlYVnyPY_re-5JceS8g6I4I7gimLSv1lVaBT8GiBXFlFSYVRi3T4oZ6Xhf0prTo2KGcd2XrKu74-IkxjXGhJO-eVYcM8YJ4U09K34tnDIanAIknUajD0lak3ZIT4CSRzcug4d8rFEItuBSzMVg3FUuAppf_li8L0mPNpkPo1Gv0ZfJJlNGPwUFGm38ZrIyGe_KQcb8sAJp0woFUD7oiJRfZVMU06R3z4unS2kjvLi9T4vvHz98m38uLy4_LebvLkrV1jyV9VItCWZQSyq7BrhqVY-7oeFSsYGzRivVDRy6mg49ryld4lYPNYW2k3pglLPT4vygu5mGEbTKnwrSik0woww74aURf1ecWYkrvxW8Zx1vWBZ4eSsQ_PUEMYnRRAXWSgd-ioI2mNC2aXGXoWd_et2b3GWQAe0BoIKPMcDyHkKw2Ict1uIubLEPW2AmctiZ-OYBUZl0M-ncs7GP098e6JAnvTUQRFRmvwna5GyS0N48LnH-QEJZ44yS9ifsIK7zCricoyAiUoHF1_1C7veREoxxn4f5T4H_6eA3XZ34yg |
| CitedBy_id | crossref_primary_10_1016_j_arbres_2022_03_011 crossref_primary_10_1186_s12931_021_01887_6 crossref_primary_10_3390_ijms25094941 crossref_primary_10_1042_BCJ20220154 crossref_primary_10_3389_fpsyg_2022_837365 crossref_primary_10_1016_j_thromres_2021_03_029 crossref_primary_10_1136_bmj_o817 crossref_primary_10_1186_s12884_021_03863_w crossref_primary_10_3389_fphar_2022_849628 crossref_primary_10_1002_jmv_28646 crossref_primary_10_1183_13993003_02447_2022 crossref_primary_10_1016_j_jjcc_2021_09_010 crossref_primary_10_1080_17474086_2022_2080051 crossref_primary_10_1111_aas_70099 crossref_primary_10_1016_j_thromres_2022_02_008 crossref_primary_10_1016_j_ajoc_2022_101430 crossref_primary_10_1002_pul2_12113 crossref_primary_10_1016_j_ijid_2024_107155 crossref_primary_10_1016_S2213_2600_23_00159_5 crossref_primary_10_1016_j_thromres_2021_03_011 crossref_primary_10_3390_healthcare11060854 crossref_primary_10_1186_s40001_022_00655_6 crossref_primary_10_1016_j_ejphar_2023_175501 crossref_primary_10_1183_13993003_00619_2022 crossref_primary_10_5315_wjh_v10_i1_1 crossref_primary_10_1016_j_cpcardiol_2022_101186 crossref_primary_10_3389_fcvm_2021_715761 crossref_primary_10_1016_j_lanepe_2025_101433 crossref_primary_10_1371_journal_pone_0270195 crossref_primary_10_3390_jcm14061909 crossref_primary_10_1001_jamainternmed_2023_2461 crossref_primary_10_1016_j_amjms_2021_06_007 crossref_primary_10_1097_MD_0000000000034250 |
| Cites_doi | 10.1093/eurheartj/ehaa254 10.1136/bmj.m1931 10.1016/j.thromres.2020.08.022 10.1136/bmj.m1845 10.1136/heartjnl-2020-317912 10.1016/0021-9681(87)90171-8 10.1161/CIRCULATIONAHA.120.048020 10.1111/jth.15179 10.1002/ejhf.1916 10.1016/j.jacc.2020.08.070 10.1007/s00134-020-06062-x 10.1016/S2352-3026(20)30217-9 10.1016/j.jacc.2020.12.039 10.1056/NEJMc2015630 10.1093/eurheartj/ehaa623 10.1016/S0140-6736(20)31356-8 10.1136/bmj.m2295 10.1038/s41591-020-0968-3 10.1001/jama.2020.13372 10.1056/NEJMc2014816 10.1016/j.thromres.2020.06.010 10.1111/jth.14768 10.1056/NEJMoa2015432 10.1016/j.jacc.2020.03.031 10.1111/j.1538-7836.2007.02664.x 10.1056/NEJMc2009787 10.7326/M20-1495 10.1136/bmj.m2334 10.1038/s41584-020-0474-5 10.1016/S0140-6736(20)30566-3 10.1016/S0140-6736(20)30920-X 10.1016/j.thromres.2020.04.028 10.1161/CIRCULATIONAHA.120.047430 |
| ContentType | Journal Article |
| Copyright | 2021 Elsevier Ltd Copyright © 2021 Elsevier Ltd. All rights reserved. 2021 Elsevier Ltd. All rights reserved. 2021 Elsevier Ltd |
| Copyright_xml | – notice: 2021 Elsevier Ltd – notice: Copyright © 2021 Elsevier Ltd. All rights reserved. – notice: 2021 Elsevier Ltd. All rights reserved. 2021 Elsevier Ltd |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1016/j.thromres.2021.03.006 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1879-2472 |
| EndPage | 23 |
| ExternalDocumentID | PMC7938753 33711754 10_1016_j_thromres_2021_03_006 S0049384821000979 1_s2_0_S0049384821000979 |
| Genre | Meta-Analysis Systematic Review Journal Article |
| GeographicLocations | England |
| GeographicLocations_xml | – name: England |
| GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 29Q 3O- 4.4 457 4CK 4G. 53G 5RE 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABJNI ABLJU ABMAC ABMZM ABOCM ABWVN ABXDB ACDAQ ACGFS ACIEU ACIUM ACLOT ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEBSH AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGHFR AGQPQ AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEB HMK HMO HVGLF HZ~ IHE J1W J5H K-O KOM L7B M29 M41 MO0 N9A O-L O9- OAUVE OC~ OO- OZT P-8 P-9 PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSZ T5K WUQ X7M Z5R ZGI ~G- ~HD 0SF AACTN AFCTW AFKWA AJOXV AMFUW NCXOZ RIG 9DU AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c647t-4fcf103e4a2a85e7c6c908b57ac3b735dcc8b7e842b97422f06db42e68adb3273 |
| ISICitedReferencesCount | 36 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000659438300004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0049-3848 1879-2472 |
| IngestDate | Tue Sep 30 15:00:38 EDT 2025 Sat Sep 27 16:58:22 EDT 2025 Thu Apr 03 07:06:38 EDT 2025 Tue Nov 18 21:40:31 EST 2025 Sat Nov 29 07:22:43 EST 2025 Sun Apr 06 06:53:53 EDT 2025 Tue Feb 25 19:58:29 EST 2025 Tue Oct 14 19:36:09 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | COVID-19 Pulmonary embolism Thrombo-embolic events Mortality |
| Language | English |
| License | Copyright © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c647t-4fcf103e4a2a85e7c6c908b57ac3b735dcc8b7e842b97422f06db42e68adb3273 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC7938753 |
| PMID | 33711754 |
| PQID | 2501265608 |
| PQPubID | 23479 |
| PageCount | 7 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7938753 proquest_miscellaneous_2501265608 pubmed_primary_33711754 crossref_primary_10_1016_j_thromres_2021_03_006 crossref_citationtrail_10_1016_j_thromres_2021_03_006 elsevier_sciencedirect_doi_10_1016_j_thromres_2021_03_006 elsevier_clinicalkeyesjournals_1_s2_0_S0049384821000979 elsevier_clinicalkey_doi_10_1016_j_thromres_2021_03_006 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-06-01 |
| PublicationDateYYYYMMDD | 2021-06-01 |
| PublicationDate_xml | – month: 06 year: 2021 text: 2021-06-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Thrombosis research |
| PublicationTitleAlternate | Thromb Res |
| PublicationYear | 2021 |
| Publisher | Elsevier Ltd |
| Publisher_xml | – name: Elsevier Ltd |
| References | Merrill, Erkan, Winakur, James (bb0035) 2020; 16 Gu, Tyagi, Jain (bb0105) 2020 Poissy, Goutay, Caplan (bb0120) 2020; 142 Wu, Mamas, Mohamed (bb0075) 2021; 107 Charlson, Pompei, Ales, MacKenzie (bb0090) 1987; 40 Gupta, Madhavan, Sehgal (bb0010) 2020; 26 bb0085 Kunutsor, Laukkanen (bb0130) 2020; 196 Helms, Tacquard, Severac (bb0145) 2020; 46 Raleigh (bb0185) 2020; 369 Kansagra, Goyal, Hamilton, Albers (bb0065) 2020; 383 Solomon, McNulty, Rana (bb0100) 2020; 383 Mafham, Spata, Goldacre (bb0070) 2020; 396 Wu, Mamas, de Belder, Deanfield, Gale (bb0080) 2021; 77 Nicolai L, Leunig A, Brambs S, et al. Vascular neutrophilic inflammation and immunothrombosis distinguish severe COVID-19 from influenza pneumonia. Journal of Thrombosis and Haemostasis; n/a(n/a). Li, Liu, Zhang (bb0050) 2020; 395 Spyropoulos, Weitz (bb0005) 2020; 142 Driggin, Madhavan, Bikdeli (bb0015) 2020; 75 Bikdeli, Madhavan, Jimenez (bb0060) 2020; 75 Oliver (bb0155) 2020; 369 Benzakoun, Hmeydia, Delabarde (bb0180) 2020; 22 Liao, Zhou, Luo (bb0025) 2020; 7 Zhou, Yu, Du (bb0045) 2020; 395 Danzi, Loffi, Galeazzi, Gherbesi (bb0040) 2020; 41 Libby, Lüscher (bb0055) 2020; 41 Bilaloglu, Aphinyanaphongs, Jones, Iturrate, Hochman, Berger (bb0140) 2020; 324 Griffin (bb0160) 2020; 369 Piazza, Campia, Hurwitz (bb0030) 2020; 76 bb0190 Ackermann, Verleden, Kuehnel (bb0150) 2020; 383 Tang, Li, Wang, Sun (bb0020) 2020; 18 van Dam, Kroft, van der Wal (bb0115) 2020; 193 Wu, Mamas, Rashid (bb0095) 2020 Iacobucci (bb0165) 2020; 369 (bb0170) 2020; 173 Thomas, Varley, Johnston (bb0125) 2020; 191 Hitos, Cannon, Cannon, Garth, Fletcher (bb0175) 2007; 5 Oxley, Mocco, Majidi (bb0135) 2020; 382 Kunutsor (10.1016/j.thromres.2021.03.006_bb0130) 2020; 196 Wu (10.1016/j.thromres.2021.03.006_bb0095) 2020 Ackermann (10.1016/j.thromres.2021.03.006_bb0150) 2020; 383 Wu (10.1016/j.thromres.2021.03.006_bb0080) 2021; 77 Oliver (10.1016/j.thromres.2021.03.006_bb0155) 2020; 369 Griffin (10.1016/j.thromres.2021.03.006_bb0160) 2020; 369 10.1016/j.thromres.2021.03.006_bb0110 Li (10.1016/j.thromres.2021.03.006_bb0050) 2020; 395 Charlson (10.1016/j.thromres.2021.03.006_bb0090) 1987; 40 Piazza (10.1016/j.thromres.2021.03.006_bb0030) 2020; 76 Thomas (10.1016/j.thromres.2021.03.006_bb0125) 2020; 191 Raleigh (10.1016/j.thromres.2021.03.006_bb0185) 2020; 369 Solomon (10.1016/j.thromres.2021.03.006_bb0100) 2020; 383 Gupta (10.1016/j.thromres.2021.03.006_bb0010) 2020; 26 (10.1016/j.thromres.2021.03.006_bb0170) 2020; 173 Liao (10.1016/j.thromres.2021.03.006_bb0025) 2020; 7 Merrill (10.1016/j.thromres.2021.03.006_bb0035) 2020; 16 Iacobucci (10.1016/j.thromres.2021.03.006_bb0165) 2020; 369 Libby (10.1016/j.thromres.2021.03.006_bb0055) 2020; 41 Helms (10.1016/j.thromres.2021.03.006_bb0145) 2020; 46 Hitos (10.1016/j.thromres.2021.03.006_bb0175) 2007; 5 Driggin (10.1016/j.thromres.2021.03.006_bb0015) 2020; 75 Bikdeli (10.1016/j.thromres.2021.03.006_bb0060) 2020; 75 Oxley (10.1016/j.thromres.2021.03.006_bb0135) 2020; 382 Benzakoun (10.1016/j.thromres.2021.03.006_bb0180) 2020; 22 Poissy (10.1016/j.thromres.2021.03.006_bb0120) 2020; 142 Danzi (10.1016/j.thromres.2021.03.006_bb0040) 2020; 41 Tang (10.1016/j.thromres.2021.03.006_bb0020) 2020; 18 Kansagra (10.1016/j.thromres.2021.03.006_bb0065) 2020; 383 Zhou (10.1016/j.thromres.2021.03.006_bb0045) 2020; 395 Mafham (10.1016/j.thromres.2021.03.006_bb0070) 2020; 396 van Dam (10.1016/j.thromres.2021.03.006_bb0115) 2020; 193 Spyropoulos (10.1016/j.thromres.2021.03.006_bb0005) 2020; 142 Wu (10.1016/j.thromres.2021.03.006_bb0075) 2021; 107 Bilaloglu (10.1016/j.thromres.2021.03.006_bb0140) 2020; 324 Gu (10.1016/j.thromres.2021.03.006_bb0105) 2020 |
| References_xml | – volume: 196 start-page: 27 year: 2020 end-page: 30 ident: bb0130 article-title: Incidence of venous and arterial thromboembolic complications in COVID-19: a systematic review and meta-analysis publication-title: Thromb. Res. – volume: 383 start-page: 120 year: 2020 end-page: 128 ident: bb0150 article-title: Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19 publication-title: N. Engl. J. Med. – volume: 41 start-page: 1858 year: 2020 ident: bb0040 article-title: Acute pulmonary embolism and COVID-19 pneumonia: a random association? publication-title: European Heart Journal – volume: 142 start-page: 184 year: 2020 end-page: 186 ident: bb0120 article-title: Pulmonary embolism in patients with COVID-19 publication-title: Circulation – volume: 383 start-page: 691 year: 2020 end-page: 693 ident: bb0100 article-title: The Covid-19 pandemic and the incidence of acute myocardial infarction publication-title: N. Engl. J. Med. – volume: 40 start-page: 373 year: 1987 end-page: 383 ident: bb0090 article-title: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation publication-title: J. Chronic Dis. – volume: 18 start-page: 844 year: 2020 end-page: 847 ident: bb0020 article-title: Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia publication-title: J. Thromb. Haemost. – volume: 107 start-page: 113 year: 2021 end-page: 119 ident: bb0075 article-title: Place and causes of acute cardiovascular mortality during the COVID-19 pandemic publication-title: Heart – volume: 383 start-page: 400 year: 2020 end-page: 401 ident: bb0065 article-title: Collateral effect of Covid-19 on stroke evaluation in the United States publication-title: N. Engl. J. Med. – volume: 396 start-page: 381 year: 2020 end-page: 389 ident: bb0070 article-title: COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England publication-title: Lancet – volume: 369 start-page: m2295 year: 2020 ident: bb0185 article-title: Tackling UK’s mortality problem: covid-19 and other causes publication-title: BMJ – volume: 75 start-page: 2950 year: 2020 end-page: 2973 ident: bb0060 article-title: COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. <span class=“subtitle”><em>JACC</em> State-of-the-Art Review</span> – reference: Nicolai L, Leunig A, Brambs S, et al. Vascular neutrophilic inflammation and immunothrombosis distinguish severe COVID-19 from influenza pneumonia. Journal of Thrombosis and Haemostasis; n/a(n/a). – ident: bb0085 article-title: User guide to mortality statistics – volume: 173 start-page: 262 year: 2020 end-page: 267 ident: bb0170 article-title: Variation in false-negative rate of reverse transcriptase polymerase chain reaction–based SARS-CoV-2 tests by time since exposure publication-title: Annals of Internal Medicine – volume: 7 year: 2020 ident: bb0025 article-title: Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study publication-title: The Lancet Haematology – volume: 77 start-page: 1141 year: 2021 end-page: 1143 ident: bb0080 article-title: Second decline in admissions with heart failure and myocardial infarction during the COVID-19 pandemic publication-title: J. Am. Coll. Cardiol. – volume: 395 start-page: 1517 year: 2020 end-page: 1520 ident: bb0050 article-title: SARS-CoV-2 and viral sepsis: observations and hypotheses publication-title: Lancet – volume: 16 start-page: 581 year: 2020 end-page: 589 ident: bb0035 article-title: Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications publication-title: Nat. Rev. Rheumatol. – volume: 76 start-page: 2060 year: 2020 end-page: 2072 ident: bb0030 article-title: Registry of arterial and venous thromboembolic complications in patients with COVID-19 publication-title: J. Am. Coll. Cardiol. – volume: 41 start-page: 3038 year: 2020 end-page: 3044 ident: bb0055 article-title: COVID-19 is, in the end, an endothelial disease publication-title: Eur. Heart J. – start-page: 1 year: 2020 end-page: 16 ident: bb0105 article-title: Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation publication-title: Nat. Rev. Cardiol. – volume: 26 start-page: 1017 year: 2020 end-page: 1032 ident: bb0010 article-title: Extrapulmonary manifestations of COVID-19 publication-title: Nat. Med. – volume: 395 start-page: 1054 year: 2020 end-page: 1062 ident: bb0045 article-title: Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study publication-title: Lancet – volume: 46 start-page: 1089 year: 2020 end-page: 1098 ident: bb0145 article-title: High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study publication-title: Intensive Care Med. – volume: 75 start-page: 2352 year: 2020 end-page: 2371 ident: bb0015 article-title: Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic publication-title: J. Am. Coll. Cardiol. – volume: 193 start-page: 86 year: 2020 end-page: 89 ident: bb0115 article-title: Clinical and computed tomography characteristics of COVID-19 associated acute pulmonary embolism: a different phenotype of thrombotic disease? publication-title: Thromb. Res. – volume: 324 start-page: 799 year: 2020 end-page: 801 ident: bb0140 article-title: Thrombosis in hospitalized patients with COVID-19 in a New York City health system publication-title: JAMA – start-page: 1 year: 2020 end-page: 9 ident: bb0095 article-title: Patient response, treatments, and mortality for acute myocardial infarction during the COVID-19 pandemic publication-title: European Heart Journal - Quality of Care and Clinical Outcomes – volume: 369 start-page: m1845 year: 2020 ident: bb0165 article-title: Covid-19: lack of capacity led to halting of community testing in march, admits deputy chief medical officer publication-title: BMJ – volume: 382 year: 2020 ident: bb0135 article-title: Large-vessel stroke as a presenting feature of Covid-19 in the young publication-title: N. Engl. J. Med. – volume: 369 start-page: m2334 year: 2020 ident: bb0155 article-title: David Oliver: Let’s be open and honest about covid-19 deaths in care homes publication-title: BMJ – volume: 22 start-page: 1046 year: 2020 end-page: 1047 ident: bb0180 article-title: Excess out-of-hospital deaths during the COVID-19 outbreak: evidence of pulmonary embolism as a main determinant publication-title: Eur. J. Heart Fail. – volume: 369 start-page: m1931 year: 2020 ident: bb0160 article-title: Covid-19: “staggering number” of extra deaths in community is not explained by covid-19 publication-title: BMJ – volume: 5 start-page: 1890 year: 2007 end-page: 1895 ident: bb0175 article-title: Effect of leg exercises on popliteal venous blood flow during prolonged immobility of seated subjects: implications for prevention of travel-related deep vein thrombosis publication-title: J. Thromb. Haemost. – volume: 191 start-page: 76 year: 2020 end-page: 77 ident: bb0125 article-title: Thrombotic complications of patients admitted to intensive care with COVID-19 at a teaching hospital in the United Kingdom publication-title: Thromb. Res. – ident: bb0190 article-title: Guidance for doctors completing medical certificates of cause of death in England and Wales – volume: 142 start-page: 129 year: 2020 end-page: 132 ident: bb0005 article-title: Hospitalized COVID-19 patients and venous thromboembolism publication-title: Circulation – volume: 41 start-page: 1858 issue: 19 year: 2020 ident: 10.1016/j.thromres.2021.03.006_bb0040 article-title: Acute pulmonary embolism and COVID-19 pneumonia: a random association? publication-title: European Heart Journal doi: 10.1093/eurheartj/ehaa254 – volume: 369 start-page: m1931 year: 2020 ident: 10.1016/j.thromres.2021.03.006_bb0160 article-title: Covid-19: “staggering number” of extra deaths in community is not explained by covid-19 publication-title: BMJ doi: 10.1136/bmj.m1931 – volume: 196 start-page: 27 year: 2020 ident: 10.1016/j.thromres.2021.03.006_bb0130 article-title: Incidence of venous and arterial thromboembolic complications in COVID-19: a systematic review and meta-analysis publication-title: Thromb. Res. doi: 10.1016/j.thromres.2020.08.022 – volume: 369 start-page: m1845 year: 2020 ident: 10.1016/j.thromres.2021.03.006_bb0165 article-title: Covid-19: lack of capacity led to halting of community testing in march, admits deputy chief medical officer publication-title: BMJ doi: 10.1136/bmj.m1845 – volume: 107 start-page: 113 year: 2021 ident: 10.1016/j.thromres.2021.03.006_bb0075 article-title: Place and causes of acute cardiovascular mortality during the COVID-19 pandemic publication-title: Heart doi: 10.1136/heartjnl-2020-317912 – volume: 40 start-page: 373 issue: 5 year: 1987 ident: 10.1016/j.thromres.2021.03.006_bb0090 article-title: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation publication-title: J. Chronic Dis. doi: 10.1016/0021-9681(87)90171-8 – volume: 142 start-page: 129 issue: 2 year: 2020 ident: 10.1016/j.thromres.2021.03.006_bb0005 article-title: Hospitalized COVID-19 patients and venous thromboembolism publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.120.048020 – ident: 10.1016/j.thromres.2021.03.006_bb0110 doi: 10.1111/jth.15179 – volume: 22 start-page: 1046 issue: 6 year: 2020 ident: 10.1016/j.thromres.2021.03.006_bb0180 article-title: Excess out-of-hospital deaths during the COVID-19 outbreak: evidence of pulmonary embolism as a main determinant publication-title: Eur. J. Heart Fail. doi: 10.1002/ejhf.1916 – volume: 76 start-page: 2060 issue: 18 year: 2020 ident: 10.1016/j.thromres.2021.03.006_bb0030 article-title: Registry of arterial and venous thromboembolic complications in patients with COVID-19 publication-title: J. Am. Coll. Cardiol. doi: 10.1016/j.jacc.2020.08.070 – volume: 46 start-page: 1089 issue: 6 year: 2020 ident: 10.1016/j.thromres.2021.03.006_bb0145 article-title: High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study publication-title: Intensive Care Med. doi: 10.1007/s00134-020-06062-x – volume: 7 issue: 9 year: 2020 ident: 10.1016/j.thromres.2021.03.006_bb0025 article-title: Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study publication-title: The Lancet Haematology doi: 10.1016/S2352-3026(20)30217-9 – volume: 77 start-page: 1141 issue: 8 year: 2021 ident: 10.1016/j.thromres.2021.03.006_bb0080 article-title: Second decline in admissions with heart failure and myocardial infarction during the COVID-19 pandemic publication-title: J. Am. Coll. Cardiol. doi: 10.1016/j.jacc.2020.12.039 – volume: 383 start-page: 691 issue: 7 year: 2020 ident: 10.1016/j.thromres.2021.03.006_bb0100 article-title: The Covid-19 pandemic and the incidence of acute myocardial infarction publication-title: N. Engl. J. Med. doi: 10.1056/NEJMc2015630 – volume: 41 start-page: 3038 issue: 32 year: 2020 ident: 10.1016/j.thromres.2021.03.006_bb0055 article-title: COVID-19 is, in the end, an endothelial disease publication-title: Eur. Heart J. doi: 10.1093/eurheartj/ehaa623 – volume: 396 start-page: 381 issue: 10248 year: 2020 ident: 10.1016/j.thromres.2021.03.006_bb0070 article-title: COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England publication-title: Lancet doi: 10.1016/S0140-6736(20)31356-8 – volume: 369 start-page: m2295 year: 2020 ident: 10.1016/j.thromres.2021.03.006_bb0185 article-title: Tackling UK’s mortality problem: covid-19 and other causes publication-title: BMJ doi: 10.1136/bmj.m2295 – volume: 26 start-page: 1017 issue: 7 year: 2020 ident: 10.1016/j.thromres.2021.03.006_bb0010 article-title: Extrapulmonary manifestations of COVID-19 publication-title: Nat. Med. doi: 10.1038/s41591-020-0968-3 – volume: 324 start-page: 799 issue: 8 year: 2020 ident: 10.1016/j.thromres.2021.03.006_bb0140 article-title: Thrombosis in hospitalized patients with COVID-19 in a New York City health system publication-title: JAMA doi: 10.1001/jama.2020.13372 – volume: 383 start-page: 400 issue: 4 year: 2020 ident: 10.1016/j.thromres.2021.03.006_bb0065 article-title: Collateral effect of Covid-19 on stroke evaluation in the United States publication-title: N. Engl. J. Med. doi: 10.1056/NEJMc2014816 – volume: 75 start-page: 2950 issue: 23 year: 2020 ident: 10.1016/j.thromres.2021.03.006_bb0060 article-title: COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. <span class=“subtitle”>JACC State-of-the-Art Review</span> – start-page: 1 year: 2020 ident: 10.1016/j.thromres.2021.03.006_bb0105 article-title: Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation publication-title: Nat. Rev. Cardiol. – volume: 193 start-page: 86 year: 2020 ident: 10.1016/j.thromres.2021.03.006_bb0115 article-title: Clinical and computed tomography characteristics of COVID-19 associated acute pulmonary embolism: a different phenotype of thrombotic disease? publication-title: Thromb. Res. doi: 10.1016/j.thromres.2020.06.010 – volume: 18 start-page: 844 issue: 4 year: 2020 ident: 10.1016/j.thromres.2021.03.006_bb0020 article-title: Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia publication-title: J. Thromb. Haemost. doi: 10.1111/jth.14768 – volume: 383 start-page: 120 issue: 2 year: 2020 ident: 10.1016/j.thromres.2021.03.006_bb0150 article-title: Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2015432 – volume: 75 start-page: 2352 issue: 18 year: 2020 ident: 10.1016/j.thromres.2021.03.006_bb0015 article-title: Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic publication-title: J. Am. Coll. Cardiol. doi: 10.1016/j.jacc.2020.03.031 – volume: 5 start-page: 1890 issue: 9 year: 2007 ident: 10.1016/j.thromres.2021.03.006_bb0175 article-title: Effect of leg exercises on popliteal venous blood flow during prolonged immobility of seated subjects: implications for prevention of travel-related deep vein thrombosis publication-title: J. Thromb. Haemost. doi: 10.1111/j.1538-7836.2007.02664.x – volume: 382 issue: 20 year: 2020 ident: 10.1016/j.thromres.2021.03.006_bb0135 article-title: Large-vessel stroke as a presenting feature of Covid-19 in the young publication-title: N. Engl. J. Med. doi: 10.1056/NEJMc2009787 – volume: 173 start-page: 262 issue: 4 year: 2020 ident: 10.1016/j.thromres.2021.03.006_bb0170 article-title: Variation in false-negative rate of reverse transcriptase polymerase chain reaction–based SARS-CoV-2 tests by time since exposure publication-title: Annals of Internal Medicine doi: 10.7326/M20-1495 – volume: 369 start-page: m2334 year: 2020 ident: 10.1016/j.thromres.2021.03.006_bb0155 article-title: David Oliver: Let’s be open and honest about covid-19 deaths in care homes publication-title: BMJ doi: 10.1136/bmj.m2334 – volume: 16 start-page: 581 issue: 10 year: 2020 ident: 10.1016/j.thromres.2021.03.006_bb0035 article-title: Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications publication-title: Nat. Rev. Rheumatol. doi: 10.1038/s41584-020-0474-5 – volume: 395 start-page: 1054 issue: 10229 year: 2020 ident: 10.1016/j.thromres.2021.03.006_bb0045 article-title: Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study publication-title: Lancet doi: 10.1016/S0140-6736(20)30566-3 – volume: 395 start-page: 1517 issue: 10235 year: 2020 ident: 10.1016/j.thromres.2021.03.006_bb0050 article-title: SARS-CoV-2 and viral sepsis: observations and hypotheses publication-title: Lancet doi: 10.1016/S0140-6736(20)30920-X – start-page: 1 year: 2020 ident: 10.1016/j.thromres.2021.03.006_bb0095 article-title: Patient response, treatments, and mortality for acute myocardial infarction during the COVID-19 pandemic publication-title: European Heart Journal - Quality of Care and Clinical Outcomes – volume: 191 start-page: 76 year: 2020 ident: 10.1016/j.thromres.2021.03.006_bb0125 article-title: Thrombotic complications of patients admitted to intensive care with COVID-19 at a teaching hospital in the United Kingdom publication-title: Thromb. Res. doi: 10.1016/j.thromres.2020.04.028 – volume: 142 start-page: 184 issue: 2 year: 2020 ident: 10.1016/j.thromres.2021.03.006_bb0120 article-title: Pulmonary embolism in patients with COVID-19 publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.120.047430 |
| SSID | ssj0017195 |
| Score | 2.5012848 |
| SecondaryResourceType | review_article |
| Snippet | Evidence supports an excess of deaths during the COVID-19 pandemic. We report the incidence and mortality of thrombo-embolic events (TE) during the COVID-19... AbstractBackgroundEvidence supports an excess of deaths during the COVID-19 pandemic. We report the incidence and mortality of thrombo-embolic events (TE)... Unlabelled Image |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 17 |
| SubjectTerms | Adolescent Adult Anticoagulants Cohort Studies COVID-19 England - epidemiology Hematology, Oncology, and Palliative Medicine Humans Incidence Mortality Pandemics Pulmonary embolism Retrospective Studies SARS-CoV-2 Thrombo-embolic events Venous Thromboembolism |
| Title | Incidence and mortality due to thromboembolic events during the COVID-19 pandemic: Multi-sourced population-based health records cohort study |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0049384821000979 https://www.clinicalkey.es/playcontent/1-s2.0-S0049384821000979 https://dx.doi.org/10.1016/j.thromres.2021.03.006 https://www.ncbi.nlm.nih.gov/pubmed/33711754 https://www.proquest.com/docview/2501265608 https://pubmed.ncbi.nlm.nih.gov/PMC7938753 |
| Volume | 202 |
| WOSCitedRecordID | wos000659438300004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1879-2472 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017195 issn: 0049-3848 databaseCode: AIEXJ dateStart: 20160601 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLa6DSFeEHfKZTISb1VK4iS1w9tUihiXgsaAvll24qgtbVo1ybQ_wb_gh3Icx1m7bmJM4qFRldiO4_PZPj72-Q5CLxMVEljfCEcqGTgBIxF0KdZzhJ_60vWkF8ZV1JKPdDhko1H0pdX6bX1hTmY0y9jpabT8r6KGeyBs7Tr7D-JuCoUb8B-EDlcQO1yvJHjo8SZQaLUvMK_Ua61qJ6UyiuZqMZcLBT_Nb10ROOXWW1Frof3P3w_fOF7UWWr78nyiv6xT-ek6xtKfdJZN1C9Hz4JJ7U3ZMRafvKOj7q6KNeraqcVk9W7NgVKTDDXG6IOfhRDmmNBMzc8g-6OscAYgHpfNDDIUiViJqahMQkf6nG9TzpEODmUCJZdjMZ-LZN2uQdbOX9mxOogcnxkezq2B3tgcpt2q0aDKXV2Eoau9gFl70P_gOTnpus5XXawulXiVD0u0mdisi3hOuMu3ku6gPULDCMbOvYPDweh9s1tFvchEyqhrvOaJfnENL1OCthc558_qrik_x3fQ7XrVgg8M2u6ilsruoZuf6nMZ99GvBnQYQIMb0GEAHS4WeBN02IAOG9DBQ4Ut6LAF3Wu8ATl8HnLYQA7XkMMGcriC3AP07e3guP_OqQN9OHEvoIUTpHHqub4KBBEsVDTuxZHLZEhF7Evqh0kcM0kVC4iE5S8hqdtLZEBUj4lE-qCAP0S72SJTjxFOaJgKKVIVkzQgAY0kCwlMpAr0dEZo0kahbXke1yz4OhjLjNvjjlNuJca1xLjrc5BYG71q8i0ND8xfc1ArWG69nGFe5oDg6-VUeT3K5PwyhLZR1OSsNWijGV_prS8s-jhMMXrfUGRqUUKiELRYTdLF2uiRQWPTBr5PNdlvAHXewGmTQNPXbz7JJuOKxh40A20seXLtr32Kbp0NHM_QbrEq1XN0Iz4pJvlqH-3QEduvu-ofOQYbcw |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Incidence+and+mortality+due+to+thromboembolic+events+during+the+COVID-19+pandemic%3A+Multi-sourced+population-based+health+records+cohort+study&rft.jtitle=Thrombosis+research&rft.au=Aktaa%2C+Suleman&rft.au=Wu%2C+Jianhua&rft.au=Nadarajah%2C+Ramesh&rft.au=Rashid%2C+Muhammad&rft.date=2021-06-01&rft.issn=0049-3848&rft_id=info:doi/10.1016%2Fj.thromres.2021.03.006&rft.externalDBID=ECK1-s2.0-S0049384821000979&rft.externalDocID=1_s2_0_S0049384821000979 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0049-3848&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0049-3848&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0049-3848&client=summon |